Maxim Group restated their buy rating on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report released on Friday, AnalystRatings.com reports. They currently have a $9.00 price target on the biotechnology company’s stock.
Separately, ValuEngine lowered Brainstorm Cell Therapeutics from a buy rating to a hold rating in a report on Wednesday, September 4th.
Shares of BCLI traded up $0.08 during trading hours on Friday, hitting $3.79. The stock had a trading volume of 168 shares, compared to its average volume of 48,366. The company has a debt-to-equity ratio of 9.34, a current ratio of 0.39 and a quick ratio of 0.39. Brainstorm Cell Therapeutics has a 12 month low of $2.92 and a 12 month high of $4.50. The firm has a market capitalization of $84.77 million, a PE ratio of -5.41 and a beta of 1.22. The stock has a fifty day moving average price of $3.81 and a 200 day moving average price of $3.86.
In other Brainstorm Cell Therapeutics news, Director Irit Arbel sold 13,332 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $3.67, for a total transaction of $48,928.44. Following the completion of the sale, the director now owns 162,499 shares of the company’s stock, valued at $596,371.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 21.20% of the company’s stock.
An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. Renaissance Technologies LLC grew its holdings in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 10.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 224,377 shares of the biotechnology company’s stock after acquiring an additional 21,720 shares during the period. Renaissance Technologies LLC owned about 1.03% of Brainstorm Cell Therapeutics worth $886,000 as of its most recent filing with the Securities & Exchange Commission. 9.32% of the stock is owned by hedge funds and other institutional investors.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Article: Dividend Aristocrat Index
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.